Effects of low-dose esketamine combined with thoracic paravertebral nerve block on postoperative recovery quality and pain in patients undergoing thoracoscopic radical resection of lung cancer

Effects of perioperative low-dose Esketamine on postoperative pain and quality of life in patients undergoing thoracoscopic lung surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069557

Enrollment

Unknown

Registered

2023-03-20

Start date

2023-03-20

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracoscopic radical resection of lung cancer

Interventions

control group:After induction, inject physiological saline intravenously, and pump physiological saline intraoperatively. PCIA: oxycodone 50mg+physiological saline=100ml

esketamine:After induction, 0.1 mg/kg of esketamine was injected intravenously, and 0.12 mg/kg/h of esketamine was pumped during surgery. PCIA: 50 mg of oxycodone+25 mg of esketamine+physiological sal

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Age: 18-65 years old; (2) American Society of Anesthesiologists (ASA) rating I-II; (3)BMI18.5-29.9kg/m 2 (4) The patient received PCIA treatment after surgery; (5) Sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Confirmed mental illness; (2) Unable to communicate due to cognitive or language impairment before surgery; (3) Preoperative history of chronic pain or opioid abuse; (4) Have a history of drug abuse and/or alcohol abuse within the past 3 months; (5) Intraoperative conversion to open chest surgery; (6) Those who enter ICU for further treatment after surgery; (7) Known allergy to esketamine; (8) Patients with any of the following contraindications for the use of esketamine injection: patients with high risk of elevated blood pressure or intracranial pressure (glaucoma) or penetrating ocular trauma who have poor control or untreated hypertension (resting systolic/diastolic blood pressure exceeding 180/110mmHg) who have not been treated or insufficiently treated with hyperthyroidism (hyperthyroidism); (9) Pregnancy or lactation; (10) I have participated in clinical research on other drugs or medical devices in the past 3 months.

Design outcomes

Primary

Measure	Time frame
pain score;quality of recovery;	—

Secondary

Measure	Time frame
Pain scores at rest and during activity;Ramsay sedation score;3D-CAM Delirium Assessment;Adverse reactions after surgery;	—

Countries

China

Contacts

Public ContactYing Wang

The First Affiliated Hospital of Zhengzhou University

gxy5582@126.com13733803893

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026